Current and future intratumoral targeted treatment for pancreatic cancer.
Ther Deliv
; 5(8): 913-26, 2014 Aug.
Article
em En
| MEDLINE
| ID: mdl-25337648
ABSTRACT
Pancreatic cancer is an insidious type of cancer with its symptoms manifested upon extensive disease. The overall 5-year survival rates between 0.4 and 4%. Surgical resection is an option for only 10% of the patients with pancreatic cancer. Local recurrence and hepatic metastases occur within 2 years after surgery. There are currently several molecular pathways investigated and novel targeted treatments are on the market. However; the nature of pancreatic cancer with its ability to spread locally in the primary site and lymph nodes indicates that further experimentation with local interventional therapies could be a future treatment proposal as palliative care or adjunct to gene therapy and chemotherapy/radiotherapy. In the current review, we will summarize the molecular pathways and present the interventional treatment options for pancreatic cancer.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Terapia de Alvo Molecular
Limite:
Humans
Idioma:
En
Revista:
Ther Deliv
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Grécia